Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d1663536e266">No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. </p>

Related collections

Author and article information

Contributors

Jaffer A. Ajani: (View ORCID Profile)

Guillaume Piessen: (View ORCID Profile)

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: April 01 2021

Publication date (Print): April 01 2021

Volume: 384

Issue: 13

Pages: 1191-1203

Affiliations

[1 ]From the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas (R.J.K.), and the University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (J.K., P.K.); the University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen–Bonn–Cologne–Duesseldorf, Gastrointestinal Cancer Group Cologne, Cologne (T.Z.), and University Medical Center of Johannes...

Article

DOI: 10.1056/NEJMoa2032125

PubMed ID: 33789008

SO-VID: eb463b3e-ffd0-45da-a85d-923fbefe9d23

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 462

See all cited by